Today, Peptonic Medical AB (“Peptonic”) publishes an operational update outlining the strategic actions and initiatives implemented and planned for the year. These efforts are expected
Peptonic Medical AB (“Peptonic”) today announces its decision to discontinue its Israeli subsidiary, a contract manufacturing organization (CMO) specializing in self-diagnostic tests. The decision will
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
Peptonic Medical AB (publ) (“Peptonic”) is taking a crucial step to establish its VagiVital brand in the U.S. market and drive sales growth of its
Peptonic Medical (publ) (“Peptonic”) is further strengthening its product portfolio with the launch of VagiVital Intimate Calming Gel, a specially formulated product designed to provide
Peptonic Medical (publ) (“Peptonic”) is expanding its portfolio of clinically proven intimate self-care products with the launch of VagiVital Active Glide, a water-based lubricant specifically
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
Peptonic Medical AB (publ) (“Peptonic”) has received notification that the Australian patent office has granted the FOAM II patent. This patent provides broad protection for
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
Peptonic Medical AB (“Peptonic”) today presents an operational update highlighting the strategic measures implemented during Anna Linton’s first 120 days as CEO. These efforts, aimed
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
Peptonic Medical AB (publ) (“Peptonic”) announces that the European Patent Office (“EPO”) has granted a patent for the relief of provoked vulvodynia (previously referred to
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN,
Peptonic Medical AB (publ) (“Peptonic”) announces today changes within its organization. Global Business Director, Erik Sundquist, and Senior Advisor, Dan Markusson, will be leaving their
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
Peptonic Medical AB (publ) (“Peptonic”) announces the appointment of Jenni Björnulfson as the company’s new Chief Financial Officer (CFO). Jenni will assume the position on
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
Peptonic Medical AB (publ) (“Peptonic”) announces that the United States Patent and Trademark Office (“USPTO”) has granted patent (16238.0043U1) for the treatment and prevention of
Peptonic Medical AB (publ) (“Peptonic”) has signed an exclusive distribution agreement with FirstAid4All to launch Peptonic’s products in intimate self-care in Belgium, the Netherlands, and
Peptonic Medical AB (“Peptonic”) clarifies short term strategic priorities under the leadership of its new CEO. Committed to achieving tangible results, the company is prioritizing
Peptonic Medical AB (publ) today announced the launch of two new products on the home market in Sweden: VagiVital Menopause FSH Test and VagiVital Urinary
Peptonic Medical AB (publ) (“Peptonic”) announced today that Doz Apotek will include the company’s product Vernivia against bacterial vaginosis in the assortment in 51 of
Peptonic Medical AB (publ) (“Peptonic”) is extending the partnership with Farmasiet that will bring the entire VagVital product portfolio to the Norwegian market. Farmasiet, Norway’s
Peptonic Medical AB (publ) (“Peptonic”) announced today that the company’s patented intimate wash, VagiVital Moisturizing V Cleanser, is being offered for sale in 293 Apoteket
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
Peptonic Medical AB (publ) (”Peptonic”) today announced that the company has signed a non-exclusive distribution agreement with Al Fotune Medical Equipment LLC for United Arab Emirate concerning the product VagiVital VS Pro. ”Al Fotune is a medical device company
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
Peptonic Medical AB (publ) (“Peptonic”) announced today that the company’s patented product for self-testing of bacterial vaginosis, VagiVital VS, is being offered for sale in
Today, November 2, 2023 the exercise period for warrants of series TO3 begins in PEPTONIC medical AB (“Peptonic” or the “Company”). The exercise period lasts
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
Peptonic CEO Erik Sundquist presented the company on Biostock Life Summit Event in Lund October 26, 2023. If you were unable to see the event
Peptonic Medical AB (publ) today announced that CEO Erik Sundquist will present the company at the BioStock Life Science Fall Summit in Lund, Sweden, on
Peptonic Medical AB (publ) today announced that it has received its first order in Central America from Windsor Pharmaceuticals. “It is gratifying that Windsor now
Peptonic Medical will present at the BioStock Life Science Fall Summit in Lund on October 25-26. Join us for our presentation at 15:30 on October 26th. Read more
Peptonic Medical AB (publ) (“Peptonic”) announced today that the company has agreed with the world’s largest retail chain Walmart to begin selling Peptonic’s self-test for
Peptonic Medical AB (publ) (“Peptonic”) today announced that it has signed an exclusive agreement regarding VagiVital’s amniotic leak self-test with Savyon Diagnostics (“Savyon”) for the
At an extraordinary general meeting on August 21, Pharmiva’s shareholders approved the planned merger between Peptonic Medical AB (“Peptonic”) and Pharmiva AB (“Pharmiva”). The merger
GROUP 2023 SECOND QUARTER (April-June) 2023 FIRST HALF YEAR (April-June) Message from our CEO Important steps towards establishing a leading Swedish Femtech Company We are
Peptonic Medical AB (publ) today announces that Albert Lindgren has been appointed Chief Financial Officer (CFO) and member of Group Management. He will take up
PEPTONIC Medical AB today announced that the company has signed a license agreement with Swiss medical device company Prima Lab SA for the sale of
Peptonic Medical AB (publ) today announces that the Stockholm District Court has rejected the Swedish Economic Crime Authority’s (EBM) claim for a corporate fine for
The FemTech companies PEPTONIC medical AB (“Peptonic”), listed on Spotlight Stock Market, and Pharmiva AB (publ) (“Pharmiva”), listed on Nasdaq First North Growth Market, have
Peptonic Medical AB (publ) today announced that the application to patent its intimate cleanser in US will be approved on June 20th2023, this according to
Peptonic Medical AB (publ) today announced that an arbitration court in China has ruled in favor of Peptonic in a dispute with Yuanjia Biotechnology Co., Ltd.
Peptonic Medical (publ) announces that the distribution agreement with medtech company GMS Healthcare Group in the United Arab Emirates (UAE) expands with three additional VagiVital® products.
PEPTONIC Medical AB announces that the company has signed a license agreement with Swiss medical technology company Prima Lab SA regarding self-tests for urinary tract
Peptonic Medical AB (publ) today announced that the company has signed an exclusive agreement with Cetro Medical for distribution of VagiVital VS Pro and VagiVital AL
GROUP 2022 FIRST QUARTER (jan-mar) Word from our CEO It is with great joy we can report that the positive development of the core business,
Peptonic Medical (PMED:SS) today announced that it has signed a non-exclusive agreement with the medical technology company Siemens Healthineers for the distribution of Peptonic’s portfolio of diagnostic
Peptonic Medical (publ) today announced that Apotek Hjärtat is initiating sales of the company’s leading intimate care product VagiVital® AktivGel in most of its physical
The Nomination Committee of Peptonic Medical AB (publ) presents the following proposals for resolutions at the Annual General Meeting on May 24 2023, regarding the number of
GROUP 2022 FOURTH QUARTER (oct-dec) FULL YEAR 2022 (jan-dec) Before inventory adjustments that fully charge quarter 4 instead of being distributed over previous quarters. From
Peptonic Medical (publ) today informed the company has signed an exclusive distributor agreement for Central Amerika with Windsor Pharmaceutical concerning the companys vaginal self tests
Peptonic Medical (publ) informed today that it’s wholly owned subsidiary Lune Group Oy has got an order from UN. The first of its kind. Earlier
Peptonic Medical (publ) informed today that it’s wholly owned subsidiary Lune Group Oy has won the Klarna Growth Award in the category “Small Business”. Lunette
Peptonic Medical (publ) announced today that its wholly owned daughter company Lune Oy Ltd has signed a marketing collaboration agreement with a Swedish company Peak
Peptonic Medical (publ) announced today that it has signed a Distribution Agreement with UCC Australia for the Australian market concerning 5 items in the Lunette
Peptonic Medical AB (publ) org nr 556776-3064 (www.aktietorget.se ticker: PMED). Group, Peptonic Medical Israel Ltd and CommonSense Marketing Inc are included from 2021-10-20. 2021 Fourth
Peptonic Medical (publ) announced today that it is now introducing VagiVital®️ range of hormone free treatments to the US market. VagiVital long term vision is to
The Company has previously announced that the Swedish Economic Crime Authority initiated an investigation in 2020 regarding a serious insider crime due to measures that
Peptonic Medical (publ) announced today that its wholly owned daughter company Lune Oy Ltd has signed a joint promotion agreement with American company Womanizer. A
At the Annual General Meeting on June 30, 2021, it was decided that the Chairman of the Board will contact the three largest shareholders in
Peptonic Medical (publ) announced today that LloydsApotek is expanding its distribution with three more products from Peptonic’s range. LloydsApotek operates 75 pharmacies in about 40
Lune Group OY incl subsidiary is consolidated in the group from 2020-06-03 Peptonic Medical AB (publ) org nr 556776-3064 (www.spotlightstockmarket.com ticker: PMED) Group, Lune Group
Peptonic Medical AB (publ) (“PMED” or “the Company”) announces today, November 4th , 2021, the intention to carry out a rights issue of units consisting of shares
Peptonic Medical (publ) today announced that the company has signed a contract amendment with Orion Corporation in Finland. The amendment concerns Peptonic’s Moisturizing V Cleanser
The acquisition also includes the US-registered subsidiary CommonSense Marketing Inc, based in New York. During year 2020 CommenSense had sales of approximately $ 2 million. CommonSense
CommonSense has been under public administration since 2021-07-07. The company is focused on women’s health and has, among other things, CE-marked products for self-testing of
Lune Group OY incl subsidiary is consolidated in the group from 2020-06-03. Peptonic Medical AB (publ) org nr 556776-3064(www.aktietorget.se ticker: PMED). Group, Lune Group OY
Peptonic Medical (publ) (‘Peptonic’ or ‘the Company’) informs that the distribution agreement with Yuanjia Biotechnology Co., Ltd. concerning VagiVital® AktivGel for the Chinese market has
Peptonic Medical AB (publ) (‘Peptonic’ or ‘the Company’) today announces that the Company has received approval from the Swedish Medical Products Agency as well as
Peptonic Medical (publ) (‘Peptonic’ or ‘the Company’) informs that the latest clinical study with VagiVital® has been published. The objective of the study was to
The annual general meeting in PEPTONIC medical AB (publ), corp. reg. no 556776-3064 (the “Company”) was held on 27 May 2021 by postal voting whereby
Peptonic Medical (publ) (“Peptonic” or “The Company”) today announced that two new products will be added under Lunette® brand. Lunette, the female, founder-led brand, created revolutionary Period
Peptonic Medical (publ) (“Peptonic” or “The Company”) today announced that Kronans Apotek launches VagiVital® Moisturizing V Cleanser in 236 of its physical stores in Sweden. Kronans Apotek
Peptonic Medical (publ) (“Peptonic” or “Bolaget”) today announced it has signed a distributor agreement with Revisage concerning sales and distribution of VagiVital® AktivGel in Poland. Revisage
Peptonic Medical AB (publ) org nr 556776-3064 (www.aktietorget.se ticker: PMED). Lune Group OY incl subsidiary is consolidated in the group from 2020-06-03. 2021 first quarter
The Board of Directors of Peptonic Medical (publ) (‘Peptonic’ or ‘the Company’ today announces that Erik Sundquist is appointed as new CEO after Johan Inborr.
Peptonic Medical AB (publ) (‘Peptonic’ or ‘the Company’) today announces the launch of a in-house developed intimate wash – VagiVital V cleanser – which is
Lune Group OY incl subsidiary is consolidated in the group from 2020-06-03. Peptonic Medical AB (publ) org nr 556776-3064 (www.aktietorget.se ticker: PMED). Group, Lune Group
Peptonic Medical AB (publ) (‘Peptonic’ or ‘the company’) has announced the appointment of Mikael Svensson, a strategic and operational leader, to the position of General
The Board of Directors of Peptonic Medical AB (the “Company”) hereby announces that the Company’s issue of shares with preferential rights of approximately SEK 25.4
Peptonic Medical AB (publ) (‘Peptonic’ or ‘the company’) announces today that they have signed an agreement with Common Sense, Ltd. (Common Sense) on the distribution
Peptonic Medical AB (publ) org nr 556776-3064(www.aktietorget.se ticker: PMED). Group, Lune Group OY incl subsidiary is included from 2020-06-03 2020 Third quarter (Jul-Sep) Net sales
Peptonic Medical AB (publ) (“Peptonic” or the “Company”) today announced that it has exercised the option to obtain a loan of 7.5 MSEK from Vidarstiftelsen according
Peptonic Medical AB (publ) (‘Peptonic’ or ‘Company’) announces today that the Company has submitted an application for patent protection for the treatment of genital fungal
Peptonic Medical (publ) (‘Peptonic’ or ‘the Company’) informs about the results of the latest clinical study with VagiVital®. The objective of this study was to
Peptonic Medical (publ) (‘Peptonic’ or ‘Company’) today announced the results of a customer survey that was performed during spring/early summer this year among VagiVital users.
Peptonic Medical AB (publ) org nr 556776-3064 (www.aktietorget.se ticker: PMED). Group, Lune Group OY incl subsidiary is included from 2020-06-03. 2020 second quarter (Apr-Jun) Net
Peptonic Medical (publ) (“Peptonic” or “Company”) today announced that it has received a purchase order from its Chinese partner Shijiazhuang Yuanjia Biotechnology Co. Ltd. (“Yuanjia Bio”) for
The extra ordinary shareholder’s meeting resolved to approve the decision by the Board of Directors to exercise the option to acquire the remaining outstanding shares
In connection with the acquisition of a majority of the shares in Lune Group Oy (“Lune”), Peptonic was granted a call option to acquire the
On 14 May 2020, Peptonic Medical AB (publ) (“Peptonic” or the “Company”) announced that the Company had entered into an agreement to acquire a majority
Peptonic Medical AB (publ) org nr 556776-3064(www.spotlightstockmarket.se ; ticker: PMED) 2020 first quarter (Jan-Mar) Net sales of products KSEK 1,781 (1,477) Gross profit KSEK 985 (802),
Peptonic Medical AB (publ) (’Peptonic’ or ’Company’) today announced that it has filed a patent application for and intimate wash based on the Company’s vaginal
Peptonic Medical AB (publ) (‘Peptonic’ or the ‘Company’) today announced that the Company has filed a patent application concerning the use of its self-care vaginal
